Interferon beta-1a (avonex) (DrugBank: Interferon beta-1a, Interferon beta)
4 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 4 |
| 26 | HTLV-1関連脊髄症 | 1 |
| 96 | クローン病 | 0 |
| 97 | 潰瘍性大腸炎 | 0 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01714089 (ClinicalTrials.gov) | March 2013 | 19/10/2012 | Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis | A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: RNS60 125 ml;Drug: RNS60 250 ml;Drug: Interferon beta 1a | Revalesio Corporation | NULL | Withdrawn | 18 Years | 50 Years | Both | 0 | Phase 2 | United States |
| 2 | NCT00146068 (ClinicalTrials.gov) | September 2004 | 1/9/2005 | EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis | Phase IV Double-Blind Randomized Study to Evaluate Safety and Efficacy of Interferon Beta-1a (Avonex) Plus Simvastatin (Zocor) Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Over a One Year Period | Multiple Sclerosis | Drug: Avonex/Zocor | University of North Carolina | NULL | Completed | 18 Years | 60 Years | Both | 30 | Phase 4 | United States |
| 3 | NCT00913666 (ClinicalTrials.gov) | November 2002 | 2/6/2009 | Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers | A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects | Multiple Sclerosis | Drug: Interferon beta-1a (Avonex) | Biogen Idec | NULL | Completed | 18 Years | 65 Years | Both | 121 | Phase 4 | NULL |
| 4 | NCT00915460 (ClinicalTrials.gov) | September 1999 | 5/6/2009 | Open-Label Safety Extension Study of Avonex | An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830 | Multiple Sclerosis | Drug: Interferon beta-1a (Avonex) | Biogen Idec | NULL | Completed | N/A | N/A | Both | 408 | Phase 4 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00001785 (ClinicalTrials.gov) | September 1998 | 3/11/1999 | Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) | Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a | HTLV-I Infection;Spinal Cord Disease;Tropical Spastic Paraparesis | Drug: Recombinant human interferon beta-1a | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 12 | Phase 2 | United States |